Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Felix Gerhard Maria Dietlein, M.D., Ph.D.

Concepts

This page shows the publications Felix Dietlein has written about Mice.
Connection Strength

0.087
  1. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell. 2015 Jul 02; 162(1):146-59.
    View in: PubMed
    Score: 0.022
  2. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov. 2014 May; 4(5):592-605.
    View in: PubMed
    Score: 0.020
  3. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer. Mol Imaging Biol. 2022 02; 24(1):115-125.
    View in: PubMed
    Score: 0.008
  4. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018 10; 37(42):5682-5693.
    View in: PubMed
    Score: 0.007
  5. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Res. 2018 08 01; 78(15):4270-4281.
    View in: PubMed
    Score: 0.007
  6. LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. Oncogene. 2018 05; 37(20):2746-2756.
    View in: PubMed
    Score: 0.007
  7. The tumour suppressor CYLD regulates the p53 DNA damage response. Nat Commun. 2016 08 26; 7:12508.
    View in: PubMed
    Score: 0.006
  8. Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget. 2015 Nov 17; 6(36):38458-68.
    View in: PubMed
    Score: 0.006
  9. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov. 2014 Feb; 4(2):246-57.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.